gabexate has been researched along with Chronic Pancreatitis in 8 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 7.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats." | 7.73 | Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| " Adverse events will be recorded." | 6.90 | A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). ( Hart, PA; Nuttall, J; Ramsey, ML, 2019) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 3.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats." | 3.73 | Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| "To investigate the effects of Guizhi Decoction, Chaihu Guizhi Decoction, Xiaochaihu Decoction and camostat on rat spontaneous chronic pancreatitis and the pathological relationships between formulas and syndromes." | 3.73 | [Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes]. ( Li, YQ; Motoo, Y; Shen, HY; Su, SB; Yoshiharu, M, 2006) |
| " Adverse events will be recorded." | 2.90 | A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). ( Hart, PA; Nuttall, J; Ramsey, ML, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramsey, ML | 1 |
| Nuttall, J | 1 |
| Hart, PA | 1 |
| Yamawaki, H | 1 |
| Futagami, S | 1 |
| Kaneko, K | 1 |
| Agawa, S | 1 |
| Higuchi, K | 1 |
| Murakami, M | 1 |
| Wakabayashi, M | 1 |
| Sakasegawa, N | 1 |
| Kodaka, Y | 1 |
| Ueki, N | 1 |
| Gudis, K | 1 |
| Kawamoto, C | 1 |
| Iwakiri, K | 1 |
| Daniluk, J | 1 |
| Liu, Y | 1 |
| Deng, D | 1 |
| Chu, J | 1 |
| Huang, H | 1 |
| Gaiser, S | 1 |
| Cruz-Monserrate, Z | 1 |
| Wang, H | 1 |
| Ji, B | 1 |
| Logsdon, CD | 1 |
| Jia, D | 1 |
| Taguchi, M | 1 |
| Otsuki, M | 3 |
| Su, SB | 1 |
| Li, YQ | 1 |
| Shen, HY | 1 |
| Motoo, Y | 2 |
| Yoshiharu, M | 1 |
| Ito, T | 1 |
| Itoi, T | 1 |
| Shimosegawa, T | 1 |
| Funakoshi, A | 1 |
| Shiratori, K | 1 |
| Naruse, S | 1 |
| Kuroda, Y | 1 |
| Nagashio, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis[NCT02693093] | Phase 1/Phase 2 | 264 participants (Actual) | Interventional | 2016-02-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gabexate and Chronic Pancreatitis
| Article | Year |
|---|---|
Action of antiproteases on fibrosis in experimental chronic pancreatitis.
Topics: Animals; Disease Models, Animal; Esters; Fibrosis; Gabexate; Guanidines; Pancreatitis, Chronic; Prot | 2007 |
Antiproteases in the treatment of chronic pancreatitis.
Topics: Animals; Esters; Gabexate; Guanidines; Humans; Pancreatitis, Chronic; Trypsin Inhibitors | 2007 |
1 trial available for gabexate and Chronic Pancreatitis
| Article | Year |
|---|---|
A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Clinical Trials, Phase I as Topic; C | 2019 |
5 other studies available for gabexate and Chronic Pancreatitis
| Article | Year |
|---|---|
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Topics: Abdominal Pain; Aged; Benzamides; Drug Therapy, Combination; Dyspepsia; Esters; Female; Gabexate; Ga | 2019 |
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Ceruletide; Cyclooxygenase 2 | 2012 |
Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
Topics: Actins; Amylases; Animals; Atrophy; Eating; Esters; Fibrosis; Gabexate; Guanidines; Interleukin-6; L | 2005 |
[Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes].
Topics: Animals; Antigens, Neoplasm; Biomarkers, Tumor; Drugs, Chinese Herbal; Esters; Gabexate; Guanidines; | 2006 |
Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Esters; Female; Follow-Up Studies; Gabexate; Guan | 2007 |